Roles of proteolysis in regulation of GPCR function

British Journal of Pharmacology

Volumn 168, Issue 3, 2013, Pages 576-590

  Cottrell, G S ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

arrestins; cell surface; endosome; GPCR; neuropeptide; peptidase; proteolysis; signalling; trafficking; ubiquitin

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; CAPTOPRIL; CHEMOKINE RECEPTOR CXCR7; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENZYME INHIBITOR; FASIDOTRIL; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEAR RECEPTOR NUR77; OMAPATRILAT; PEPTIDASE; PEPTIDASE INHIBITOR; PEPTIDE; PLACEBO; PROTEIN TYROSINE KINASE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; THROMBIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL SURFACE; CONGESTIVE HEART FAILURE; DOWN REGULATION; DRUG MECHANISM; ENDOSOME; ENZYME ACTIVATION; HEART HYPERTROPHY; HUMAN; HYPERTENSION; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; UBIQUITINATION;

ANIMALS; ENDOSOMES; HUMANS; PEPTIDE HYDROLASES; PROTEOLYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84872389663     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02234.x     Document Type: Review

References (170)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, et al. (2002). Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35-40.
3. Bennett VJ, Perrine SA, Simmons MA, (2002). A novel mechanism of neurokinin-1 receptor resensitization. J Pharmacol Exp Ther 303: 1155-1162.
4. Bennett VJ, Perrine SA, Simmons MA, (2005). Neurokinin-1 receptor resensitization precedes receptor recycling. J Pharmacol Exp Ther 313: 1347-1354.
5. Berthouze M, Venkataramanan V, Li Y, Shenoy SK, (2009). The deubiquitinases USP33 and USP20 coordinate beta2 adrenergic receptor recycling and resensitization. EMBO J 28: 1684-1696.
6. Blackhart BD, Ruslim-Litrus L, Lu CC, Alves VL, Teng W, Scarborough RM, et al. (2000). Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol Pharmacol 58: 1178-1187.
7. Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al. (1996). Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 314 (Pt 3): 1009-1016.
8. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A, (2005). PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-313.
9. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I, (1985). Calcitonin gene-related peptide is a potent vasodilator. Nature 313: 54-56.
10. Bralet J, Marie C, Mossiat C, Lecomte JM, Gros C, Schwartz JC, (1994). Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. J Pharmacol Exp Ther 270: 8-14.
11. Brun P, Mastrotto C, Beggiao E, Stefani A, Barzon L, Sturniolo GC, et al. (2005). Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 288: G621-G629.
12. Burger MM, (1970). Proteolytic enzymes initiating cell division and escape from contact inhibition of growth. Nature 227: 170-171.
13. Buteau J, Foisy S, Joly E, Prentki M, (2003). Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52: 124-132.
14. Cain CC, Sipe DM, Murphy RF, (1989). Regulation of endocytic pH by the Na+,K+-ATPase in living cells. Proc Natl Acad Sci U S A 86: 544-548.
15. Camerer E, Huang W, Coughlin SR, (2000). Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A 97: 5255-5260.
16. Canals M, Scholten DJ, de, Munnik S, Han MK, Smit MJ, Leurs R, (2012). Ubiquitination of CXCR7 controls receptor trafficking. PLoS ONE 7: e34192.
17. Carney DH, Cunningham DD, (1977). Initiation of check cell division by trypsin action at the cell surface. Nature 268: 602-606.
18. Carney DH, Cunningham DD, (1978). Transmembrane action of thrombin initiates chick cell division. J Supramol Struct 9: 337-350.
19. Castagliuolo I, Wang CC, Valenick L, Pasha A, Nikulasson S, Carraway RE, et al. (1999). Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest 103: 843-849.
20. Castro-Obregon S, Rao RV, del Rio G, Chen SF, Poksay KS, Rabizadeh S, et al. (2004). Alternative, nonapoptotic programmed cell death: mediation by arrestin 2, ERK2, and Nur77. J Biol Chem 279: 17543-17553.
21. Cattaruzza F, Cottrell GS, Vaksman N, Bunnett NW, (2009). Endothelin-converting enzyme 1 promotes re-sensitization of neurokinin 1 receptor-dependent neurogenic inflammation. Br J Pharmacol 156: 730-739.
22. Chen LB, Buchanan JM, (1975). Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci U S A 72: 131-135.
23. Cheng ZJ, Vapaatalo H, Mervaala E, (2005). Angiotensin II and vascular inflammation. Med Sci Monit 11: RA194-RA205.
24. CONSENSUS (1987). Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316: 1429-1435.
25. Cottrell GS, Amadesi S, Grady EF, Bunnett NW, (2004). Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 279: 13532-13539.
26. Cottrell GS, Padilla B, Pikios S, Roosterman D, Steinhoff M, Grady EF, et al. (2007). Post-endocytic sorting of calcitonin receptor-like receptor and receptor activity-modifying protein 1. J Biol Chem 282: 12260-12271.
27. Cottrell GS, Padilla BE, Amadesi S, Poole DP, Murphy JE, Hardt M, et al. (2009). Endosomal endothelin-converting enzyme-1: a regulator of beta-arrestin-dependent ERK signaling. J Biol Chem 284: 22411-22425.
28. Cumashi A, Ansuini H, Celli N, De Blasi A, O'Brien PJ, Brass LF, et al. (2001). Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets. Thromb Haemost 85: 533-538.
29. Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Ferguson SS, Caron MG, et al. (1998). Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 273: 685-688.
30. Daub H, Weiss FU, Wallasch C, Ullrich A, (1996). Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379: 557-560.
31. Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, et al. (2005). Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens 18 (12 Pt 1): 1606-1613.
32. Daull P, Blouin A, Belleville K, Beaudoin M, Arsenault D, Leonard H, et al. (2006a). Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats. Exp Biol Med (Maywood) 231: 830-833.
33. Daull P, Lepage R, Benrezzak O, Cayer J, Beaudoin M, Belleville K, et al. (2006b). The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats. Drug Chem Toxicol 29: 183-202.
34. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW, (2000). beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148: 1267-1281.
35. Dery O, Defea KA, Bunnett NW, (2001). Protein kinase C-mediated desensitization of the neurokinin 1 receptor. Am J Physiol Cell Physiol 280: C1097-C1106.
36. Dive V, Chang CF, Yiotakis A, Sturrock ED, (2009). Inhibition of zinc metallopeptidases in cardiovascular disease-from unity to trinity, or duality? Curr Pharm Des 15: 3606-3621.
37. Dulon S, Cande C, Bunnett NW, Hollenberg MD, Chignard M, Pidard D, (2003). Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases. Am J Respir Cell Mol Biol 28: 339-346.
38. Dulon S, Leduc D, Cottrell GS, D'Alayer J, Hansen KK, Bunnett NW, et al. (2005). Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. Am J Respir Cell Mol Biol 32: 411-419.
39. Eguchi S, Inagami T, (2000). Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul Pept 91: 13-20.
40. Eguchi S, Frank GD, Mifune M, Inagami T, (2003). Metalloprotease- dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. Biochem Soc Trans 31 (Pt 6): 1198-1202.
41. Feistritzer C, Riewald M, (2005). Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105: 3178-3184.
42. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, et al. (2005). Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280: 17286-17293.
43. Forgac M, Cantley L, Wiedenmann B, Altstiel L, Branton D, (1983). Clathrin-coated vesicles contain an ATP-dependent proton pump. Proc Natl Acad Sci U S A 80: 1300-1303.
44. Goh FG, Ng PY, Nilsson M, Kanke T, Plevin R, (2009). Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling. Br J Pharmacol 158: 1695-1704.
45. Gooz P, Dang Y, Higashiyama S, Twal WO, Haycraft CJ, Gooz M, (2012). A disintegrin and metalloenzyme (ADAM) 17 activation is regulated by alpha5beta1 integrin in kidney mesangial cells. PLoS ONE 7: e33350.
46. Gros C, Noel N, Souque A, Schwartz JC, Danvy D, Plaquevent JC, et al. (1991). Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci U S A 88: 4210-4214.
47. Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, Weitz D, et al. (1981). Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther 216: 552-557.
48. Gschwind A, Hart S, Fischer OM, Ullrich A, (2003). TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 22: 2411-2421.
49. Hammond-Martel I, Yu H, Affar B, (2012). Roles of ubiquitin signaling in transcription regulation. Cell Signal 24: 410-421.
50. Hart S, Fischer OM, Prenzel N, Zwick-Wallasch E, Schneider M, Hennighausen L, et al. (2005). GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol Chem 386: 845-855.
51. Hasdemir B, Murphy JE, Cottrell GS, Bunnett NW, (2009). Endosomal deubiquitinating enzymes control ubiquitination and down-regulation of protease-activated receptor 2. J Biol Chem 284: 28453-28466.
52. Hasdemir B, Mahajan S, Bunnett NW, Liao M, Bhargava A, (2012). Endothelin-converting enzyme-1 actions determine differential trafficking and signaling of corticotropin-releasing factor receptor 1 at high agonist concentrations. Mol Endocrinol 26: 681-695.
53. Hicke L, Riezman H, (1996). Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis. Cell 84: 277-287.
54. Hilairet S, Belanger C, Bertrand J, Laperriere A, Foord SM, Bouvier M, (2001). Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin. J Biol Chem 276: 42182-42190.
55. Hislop JN, von Zastrow M, (2011). Role of ubiquitination in endocytic trafficking of G-protein-coupled receptors. Traffic 12: 137-148.
56. Hislop JN, Henry AG, Marchese A, von, Zastrow M, (2009). Ubiquitination regulates proteolytic processing of G protein-coupled receptors after their sorting to lysosomes. J Biol Chem 284: 19361-19370.
57. Hislop JN, Henry AG, von, Zastrow M, (2011). Ubiquitination in the first cytoplasmic loop of mu-opioid receptors reveals a hierarchical mechanism of lysosomal down-regulation. J Biol Chem 286: 40193-40204.
58. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM, (2005). Shedding light on ADAM metalloproteinases. Trends Biochem Sci 30: 413-422.
59. Ikeo T, Yabana H, Kurosawa H, Kaburaki M, Kikkawa K, Narita H, et al. (1992). Acute hemodynamic effects of the active metabolite of imidapril, (4S)-3-((2S)-2-[N-((1S)-1-carboxy-3-phenyl-propyl)amino]propionyl)-1- methyl-2-oxoimidazolidine-4-carboxylic acid, and enalaprilat in anesthetized dogs. Arzneimittelforschung 42: 1109-1114.
60. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, et al. (1997). Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386: 502-506.
61. Ishihara H, Zeng D, Connolly AJ, Tam C, Coughlin SR, (1998). Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. Blood 91: 4152-4157.
62. Itoh Y, Joh T, Tanida S, Sasaki M, Kataoka H, Itoh K, et al. (2005). IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. Cytokine 29: 275-282.
63. Jacob C, Cottrell GS, Gehringer D, Schmidlin F, Grady EF, Bunnett NW, (2005). c-Cbl mediates ubiquitination, degradation, and down-regulation of human protease-activated receptor 2. J Biol Chem 280: 16076-16087.
64. Johnson GD, Stevenson T, Ahn K, (1999). Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem 274: 4053-4058.
65. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, et al. (1998). A dual thrombin receptor system for platelet activation. Nature 394: 690-694.
66. Kawamura M, Kuraishi Y, Minami M, Satoh M, (1989). Antinociceptive effect of intrathecally administered antiserum against calcitonin gene-related peptide on thermal and mechanical noxious stimuli in experimental hyperalgesic rats. Brain Res 497: 199-203.
67. Kawasaki Y, Kohno T, Zhuang ZY, Brenner GJ, Wang H, Van Der Meer C, et al. (2004). Ionotropic and metabotropic receptors, protein kinase A, protein kinase C, and Src contribute to C-fiber-induced ERK activation and cAMP response element-binding protein phosphorylation in dorsal horn neurons, leading to central sensitization. J Neurosci 24: 8310-8321.
68. Khimji AK, Rockey DC, (2010). Endothelin-biology and disease. Cell Signal 22: 1615-1625.
69. Kuraishi Y, Nanayama T, Ohno H, Minami M, Satoh M, (1988). Antinociception induced in rats by intrathecal administration of antiserum against calcitonin gene-related peptide. Neurosci Lett 92: 325-329.
70. Kuwasako K, Shimekake Y, Masuda M, Nakahara K, Yoshida T, Kitaura M, et al. (2000). Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J Biol Chem 275: 29602-29609.
71. Lamberts SW, Bakker WH, Reubi JC, Krenning EP, (1990). Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323: 1246-1249.
72. Law IK, Murphy JE, Bakirtzi K, Bunnett NW, Pothoulakis C, (2012). Neurotensin-induced proinflammatory signaling in human colonocytes is regulated by beta-arrestins and endothelin-converting enzyme-1-dependent endocytosis and resensitization of neurotensin receptor 1. J Biol Chem 287: 15066-15075.
73. Lee FS, Chao MV, (2001). Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci U S A 98: 3555-3560.
74. Li JG, Haines DS, Liu-Chen LY, (2008). Agonist-promoted Lys63-linked polyubiquitination of the human kappa-opioid receptor is involved in receptor down-regulation. Mol Pharmacol 73: 1319-1330.
75. Linseman DA, Benjamin CW, Jones DA, (1995). Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem 270: 12563-12568.
76. Lundberg JM, Franco-Cereceda A, Hua X, Hokfelt T, Fischer JA, (1985). Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol 108: 315-319.
77. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. (1999). Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283: 655-661.
78. McDonald DM, (1988). Neurogenic inflammation in the rat trachea. I. Changes in venules, leucocytes and epithelial cells. J Neurocytol 17: 583-603.
79. McDonald DM, Mitchell RA, Gabella G, Haskell A, (1988). Neurogenic inflammation in the rat trachea. II. Identity and distribution of nerves mediating the increase in vascular permeability. J Neurocytol 17: 605-628.
80. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393: 333-339.
81. McLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, Hamm HE, (2005). Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 280: 25048-25059.
82. McNeish AJ, Roux BT, Aylett S-B, Maassen Van Den Brink A, Cottrell GS, (2012). Endosomal proteolysis regulates calcitonin gene-related peptide responses in mesenteric arteries. Br J Pharmacol 167: 1679-1690.
83. Malik R, Soh UJ, Trejo J, Marchese A, (2012). Novel roles for the E3 ubiquitin ligase atrophin-interacting protein 4 and signal transduction adaptor molecule 1 in G protein-coupled receptor signaling. J Biol Chem 287: 9013-9027.
84. Malynn BA, Ma A, (2010). Ubiquitin makes its mark on immune regulation. Immunity 33: 843-852.
85. Mannaioni G, Orr AG, Hamill CE, Yuan H, Pedone KH, McCoy KL, et al. (2008). Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1. J Biol Chem 283: 20600-20611.
86. Mantyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Mantyh CR, et al. (1995). Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 268: 1629-1632.
87. Marchese A, Benovic JL, (2001). Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem 276: 45509-45512.
88. Matsas R, Kenny AJ, Turner AJ, (1984). The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11. Biochem J 223: 433-440.
89. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, et al. (2000). The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275: 9572-9580.
90. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, et al. (2005). G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 280: 26592-26599.
91. Milojevic T, Reiterer V, Stefan E, Korkhov VM, Dorostkar MM, Ducza E, et al. (2006). The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor. Mol Pharmacol 69: 1083-1094.
92. Mogi M, Iwai M, Horiuchi M, (2009). New insights into the regulation of angiotensin receptors. Curr Opin Nephrol Hypertens 18: 138-143.
93. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, et al. (1997). Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 272: 4043-4049.
94. Moore CA, Milano SK, Benovic JL, (2007). Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69: 451-482.
95. Moore EL, Salvatore CA, (2012). Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. Br J Pharmacol 166: 66-78.
96. Moore RH, Tuffaha A, Millman EE, Dai W, Hall HS, Dickey BF, et al. (1999). Agonist-induced sorting of human beta2-adrenergic receptors to lysosomes during downregulation. J Cell Sci 112 (Pt 3): 329-338.
97. Muller S, Dennemarker J, Reinheckel T, (2012). Specific functions of lysosomal proteases in endocytic and autophagic pathways. Biochim Biophys Acta 1824: 34-43.
98. Murphy JE, Padilla BE, Hasdemir B, Cottrell GS, Bunnett NW, (2009). Endosomes: a legitimate platform for the signaling train. Proc Natl Acad Sci U S A 106: 17615-17622.
99. Murphy JE, Roosterman D, Cottrell GS, Padilla BE, Feld M, Brand E, et al. (2011). Protein phosphatase 2A mediates resensitization of the neurokinin 1 receptor. Am J Physiol Cell Physiol 301: C780-C791.
100. Myers TJ, Brennaman LH, Stevenson M, Higashiyama S, Russell WE, Lee DC, et al. (2009). Mitochondrial reactive oxygen species mediate GPCR-induced TACE/ADAM17-dependent transforming growth factor-alpha shedding. Mol Biol Cell 20: 5236-5249.
101. Neal B, MacMahon S, Ohkubo T, Brnabic A, Tonkin A, (2002). Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. J Renin Angiotensin Aldosterone Syst 3: 270-276.
102. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J, (1994). Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 91: 9208-9212.
103. Nystedt S, Emilsson K, Larsson AK, Strombeck B, Sundelin J, (1995a). Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem 232: 84-89.
104. Nystedt S, Larsson AK, Aberg H, Sundelin J, (1995b). The mouse proteinase-activated receptor-2 cDNA and gene. Molecular cloning and functional expression. J Biol Chem 270: 5950-5955.
105. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS, (2000). Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275: 17201-17210.
106. Ohtsu H, Dempsey PJ, Eguchi S, (2006). ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 291: C1-10.
107. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W, (2004). Regulation and function of somatostatin receptors. J Neurochem 89: 1057-1091.
108. Ondetti MA, Rubin B, Cushman DW, (1977). Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196: 441-444.
109. Padilla BE, Cottrell GS, Roosterman D, Pikios S, Muller L, Steinhoff M, et al. (2007). Endothelin-converting enzyme-1 regulates endosomal sorting of calcitonin receptor-like receptor and beta-arrestins. J Cell Biol 179: 981-997.
110. Paolillo M, Schinelli S, (2008). Therapeutic targeting of g-protein coupled receptor-mediated epidermal growth factor receptor transactivation in human glioma brain tumors. Mini Rev Med Chem 8: 1418-1428.
111. Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L, Jansen I, Olesen J, (1991). Calcitonin gene-related peptide, neurokinin A and substance P: effects on nociception and neurogenic inflammation in human skin and temporal muscle. Peptides 12: 333-337.
112. Pelayo JC, Poole DP, Steinhoff M, Cottrell GS, Bunnett NW, (2011). Endothelin-converting enzyme-1 regulates trafficking and signalling of the neurokinin 1 receptor in endosomes of myenteric neurones. J Physiol 589 (Pt 21): 5213-5230.
113. Pierce KL, Tohgo A, Ahn S, Field ME, Luttrell LM, Lefkowitz RJ, (2001). Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding. J Biol Chem 276: 23155-23160.
114. Pietri M, Schneider B, Mouillet-Richard S, Ermonval M, Mutel V, Launay JM, et al. (2005). Reactive oxygen species-dependent TNF-alpha converting enzyme activation through stimulation of 5-HT2B and alpha1D autoreceptors in neuronal cells. FASEB J 19: 1078-1087.
115. Pitcher J, Lohse MJ, Codina J, Caron MG, Lefkowitz RJ, (1992). Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. Biochemistry 31: 3193-3197.
116. Pitcher JA, Payne ES, Csortos C, DePaoli-Roach AA, Lefkowitz RJ, (1995). The G-protein-coupled receptor phosphatase: a protein phosphatase type 2A with a distinct subcellular distribution and substrate specificity. Proc Natl Acad Sci U S A 92: 8343-8347.
117. Porrello ER, Delbridge LM, Thomas WG, (2009). The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci 14: 958-972.
118. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, et al. (1999). EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888.
119. Quinton TM, Kim S, Derian CK, Jin J, Kunapuli SP, (2004). Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 279: 18434-18439.
120. Raddant AC, Russo AF, (2011). Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med 13: e36.
121. Ramachandran R, Mihara K, Mathur M, Rochdi MD, Bouvier M, Defea K, et al. (2009). Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Mol Pharmacol 76: 791-801.
122. Ramachandran R, Mihara K, Chung H, Renaux B, Lau CS, Muruve DA, et al. (2011). Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). J Biol Chem 286: 24638-24648.
123. Ramaekers CH, Wouters BG, (2011). Regulatory functions of ubiquitin in diverse DNA damage responses. Curr Mol Med 11: 152-169.
124. Rao GN, Delafontaine P, Runge MS, (1995). Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-gamma 1 in rat aortic smooth muscle cells. J Biol Chem 270: 27871-27875.
125. Rawlings ND, Barrett AJ, Bateman A, (2012). MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 40 (Database issue): D343-D350.
126. Regamey F, Maillard M, Nussberger J, Brunner HR, Burnier M, (2002). Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension 40: 266-272.
127. Reubi JC, Hacki WH, Lamberts SW, (1987a). Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 65: 1127-1134.
128. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW, (1987b). Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 47: 5758-5764.
129. Reubi JC, Maurer R, von, Werder K, Torhorst J, Klijn JG, Lamberts SW, (1987c). Somatostatin receptors in human endocrine tumors. Cancer Res 47: 551-558.
130. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W, (2002). Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296: 1880-1882.
131. Roosterman D, Cottrell GS, Padilla BE, Muller L, Eckman CB, Bunnett NW, et al. (2007). Endothelin-converting enzyme 1 degrades neuropeptides in endosomes to control receptor recycling. Proc Natl Acad Sci U S A 104: 11838-11843.
132. Roosterman D, Kempkes C, Cottrell GS, Padilla BE, Bunnett NW, Turck CW, et al. (2008). Endothelin-converting enzyme-1 degrades internalized somatostatin-14. Endocrinology 149: 2200-2207.
133. Roth NS, Campbell PT, Caron MG, Lefkowitz RJ, Lohse MJ, (1991). Comparative rates of desensitization of beta-adrenergic receptors by the beta-adrenergic receptor kinase and the cyclic AMP-dependent protein kinase. Proc Natl Acad Sci U S A 88: 6201-6204.
134. Rothmeier AS, Ruf W, (2012). Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol 34: 133-149.
135. Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR, (2000). Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 275: 6819-6823.
136. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR, (2001). Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413: 74-78.
137. Scase TJ, Heath MF, Evans RJ, (1997). Cloning of PAR3 cDNA from human platelets, and human erythroleukemic and human promonocytic cell lines. Blood 90: 2113-2114.
138. Schafer B, Marg B, Gschwind A, Ullrich A, (2004). Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 279: 47929-47938.
139. Sefton BM, Rubin H, (1970). Release from density dependent growth inhibition by proteolytic enzymes. Nature 227: 843-845.
140. Shenoy SK, Lefkowitz RJ, (2003). Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. J Biol Chem 278: 14498-14506.
141. Shenoy SK, Lefkowitz RJ, (2011). beta-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32: 521-533.
142. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ, (2001). Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294: 1307-1313.
143. Shenoy SK, Barak LS, Xiao K, Ahn S, Berthouze M, Shukla AK, et al. (2007). Ubiquitination of beta-arrestin links seven-transmembrane receptor endocytosis and ERK activation. J Biol Chem 282: 29549-29562.
144. Shenoy SK, Modi AS, Shukla AK, Xiao K, Berthouze M, Ahn S, et al. (2009). Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2. Proc Natl Acad Sci U S A 106: 6650-6655.
145. Showkathali R, Natarajan A, (2012). Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. Curr Cardiol Rev PMID: 22935021 [Epub ahead of print].
146. Simaan M, Bedard-Goulet S, Fessart D, Gratton JP, Laporte SA, (2005). Dissociation of beta-arrestin from internalized bradykinin B2 receptor is necessary for receptor recycling and resensitization. Cell Signal 17: 1074-1083.
147. SOLVD (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325: 293-302.
148. Starostina NG, Kipreos ET, (2012). Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol 22: 33-41.
149. Suzuki T, Moraes TJ, Vachon E, Ginzberg HH, Huang TT, Matthay MA, et al. (2005). Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells. Am J Respir Cell Mol Biol 33: 231-247.
150. Suzuki T, Yamashita C, Zemans RL, Briones N, Van Linden A, Downey GP, (2009). Leukocyte elastase induces lung epithelial apoptosis via a PAR-1-, NF-kappaB-, and p53-dependent pathway. Am J Respir Cell Mol Biol 41: 742-755.
151. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS, (2000). Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275: 26333-26342.
152. Tanida S, Kataoka H, Mizoshita T, Shimura T, Kamiya T, Joh T, (2010). Intranuclear translocation signaling of HB-EGF carboxy-terminal fragment and mucosal defense through cell proliferation and migration in digestive tracts. Digestion 82: 145-149.
153. Tanowitz M, Von Zastrow M, (2002). Ubiquitination-independent trafficking of G protein-coupled receptors to lysosomes. J Biol Chem 277: 50219-50222.
154. Thanawala V, Kadam VJ, Ghosh R, (2008). Enkephalinase inhibitors: potential agents for the management of pain. Curr Drug Targets 9: 887-894.
155. Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY, (2004). CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 44 (Suppl. 1): S211-S215.
156. Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, et al. (2009). Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137: 332-343.
157. Tsao PI, von Zastrow M, (2000). Type-specific sorting of G protein-coupled receptors after endocytosis. J Biol Chem 275: 11130-11140.
158. Umekawa K, Hasegawa H, Tsutsumi Y, Sato K, Matsumura Y, Ohashi N, (2000). Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn J Pharmacol 84: 7-15.
159. Urban JD, Clarke WP, von, Zastrow M, Nichols DE, Kobilka B, Weinstein H,
160. Vu TK, Hung DT, Wheaton VI, Coughlin SR, (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068.
161. Vucic D, Dixit VM, Wertz IE, (2011). Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 12: 439-452.
162. Wolfe BL, Marchese A, Trejo J, (2007). Ubiquitination differentially regulates clathrin-dependent internalization of protease-activated receptor-1. J Cell Biol 177: 905-916.
163. Wyatt D, Malik R, Vesecky AC, Marchese A, (2011). Small ubiquitin-like modifier modification of arrestin-3 regulates receptor trafficking. J Biol Chem 286: 3884-3893.
164. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, et al. (1998). Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 95: 6642-6646.
165. Yan Y, Shirakabe K, Werb Z, (2002). The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 158: 221-226.
166. Yoshida N, Yoshikawa T, (2008). Basic and translational research on proteinase-activated receptors: implication of proteinase/proteinase-activated receptor in gastrointestinal inflammation. J Pharmacol Sci 108: 415-421.
167. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153.
168. von Zastrow M, Sorkin A, (2007). Signaling on the endocytic pathway. Curr Opin Cell Biol 19: 436-445.
169. Zhang Z, Oliver P, Lancaster JR Jr, Schwarzenberger PO, Joshi MS, Cork J, et al. (2001). Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J 15: 303-305.
170. Zwick E, Wallasch C, Daub H, Ullrich A, (1999). Distinct calcium-dependent pathways of epidermal growth factor receptor transactivation and PYK2 tyrosine phosphorylation in PC12 cells. J Biol Chem 274: 20989-20996.